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NORTH-SOUTH COLLABORATIONS TO PROMOTE HEALTH
INNOVATION IN AFRICA
Dennis C. Liotta∗
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Liza Vertinsky∗∗∗∗
ABSTRACT
The significant interest in and reference to regional innovation networks
for health capacity building within international and regional public health
and development strategies has not been matched with the operational support
they need. There is little guidance about how to create and sustain such
networks and about how north-south collaborations can contribute to their
success. This Article describes a model for building African health capacity
through regional health innovation networks that focuses on the complete
pathway from idea to commercialization of health technologies, and it suggests
guidelines for effective north-south collaborations to support this approach. In
doing so, the Article highlights the importance of local legal and business
capacity building as part of a product-focused, network-based health
innovation strategy.
INTRODUCTION
Developing the health products needed, in the form and at the price needed,
to combat diseases that disproportionately impact African countries, requires
the strengthening of African capacity to discover, develop, and commercialize
health technologies.1 Strengthening African capacity in an effective and
sustainable way requires African-led identification of promising technologies,
leveraging of existing capacity at all stages of the research and product
development pipeline, and building new capacity where gaps exist.2 A major
∗
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1
Health technologies include medical devices, diagnostics, drugs, and vaccines.
2
See, e.g., COUNCIL ON HEALTH RESEARCH FOR DEV. & NEW P’SHIP FOR AFR.’S DEV.,
STRENGTHENING PHARMACEUTICAL INNOVATION IN AFRICA: DESIGNING STRATEGIES FOR NATIONAL
PHARMACEUTICAL INNOVATION (2010); Michel Sidibé et al., Editorial, Commodities for Better Health in
Africa—Time to Invest Locally, 92 BULL. WORLD HEALTH ORG. 387 (2014).
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gap in developing African health technologies occurs at the point of moving
early-stage technologies into development and commercialization.3 Fostering
regional networks that connect existing capacities within and across African
countries in ways that support the development and commercialization of
African health products is critical to the success of capacity-building efforts.4
This regional network-based capacity-building approach informs the
Global Strategy and Plan of Action on Public Health, Innovation and
Intellectual Property (“Global Strategy”), a global health initiative adopted by
the World Health Assembly in 2008.5 The Global Strategy marks a shift in
international thinking about how to address diseases, especially neglected
diseases, in developing countries. It reflects an international consensus on the
need to build research and development (R&D) capacity in developing
countries to enable them to address those diseases that disproportionately
impact them.6 The Global Strategy’s plan incorporates regional innovation
networks as proposed mechanisms for building health capacity.7 At roughly the
same time as negotiations over the Global Strategy, the Summit of the African
Union adopted the Pharmaceutical Manufacturing Plan for Africa as part of its
effort to establish a coordinated regional approach to local production of health
products.8 This plan promotes a vision of a competitive, integrated, and
sustainable pharmaceutical manufacturing industry in Africa capable of
responding to the continent’s needs for medical therapies.9 It, too, emphasizes
the importance of network building and collaboration at the regional level.10 A
subsequent initiative spearheaded by the New Partnership for Africa’s
Development (NEPAD) in 2010, Strengthening Pharmaceutical Innovation in
Africa, has provided an assessment both of existing pharmaceutical capacities

3
See, e.g., Peter A. Singer et al., Commercializing African Health Research: Building Life Science
Convergence Platforms, 5 GLOBAL F. UPDATE ON RESEARCH FOR HEALTH 143 (2008); see also Ken Simiyu et
al., Stagnant Health Technologies in Africa, 330 SCI. 1483 (2010).
4
See, e.g., Regional Network for Drugs and Diagnostics Innovation Exemplified by ANDI:
Background Paper for Executive Board, WORLD HEALTH ORG., http://www.who.int/phi/documents/
RegionalandnationalnetworksAfrican.pdf (last visited Nov. 14, 2017).
5
WORLD HEALTH ORG., GLOBAL STRATEGY AND PLAN OF ACTION ON PUBLIC HEALTH, INNOVATION
AND INTELLECTUAL PROPERTY 1 (2011).
6
See, e.g., COUNCIL ON HEALTH RESEARCH FOR DEV. & NEW P’SHIP FOR AFR.’S DEV., supra note 2, at
11.
7
See Regional Network for Drugs and Diagnostics Innovation Exemplified by ANDI: Background
Paper for Executive Board, supra note 4.
8
See AFRICAN UNION COMM’N & UNITED NATIONS INDUS. DEV. ORG., PHARMACEUTICAL
MANUFACTURING PLAN FOR AFRICA: BUSINESS PLAN 1 (2012).
9
See id.
10
See id. (outlining a business plan designed to accelerate implementation of Pharmaceutical
Manufacturing Plan for Africa).
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and of the potential for engaging in local research and production of health
technologies through regional innovation networks.11 A network-based
approach to developing health capacity similarly resonates with the United
Nations’ Sustainable Development Goals,12 the objectives in the African
Union’s Agenda 2063 development plan,13 and the Science, Technology and
Innovation Strategy for Africa 2024.14
While regional networks for building health innovation capacity feature
prominently in these international and regional strategies for addressing
African health and development challenges, there is little guidance as to what
these networks should look like, how to create and sustain them, and how
north-south collaborations can best contribute to their success.15 As NEPAD
notes in its Strengthening Pharmaceutical Innovation in Africa report,
initiatives like the Global Strategy and the Pharmaceutical Manufacturing Plan
“are aspirational statements that need to be translated into work plans and
approaches to implementation.”16 This Article responds to that implementation
gap by drawing from the experiences of the African Network for Drug and
Diagnostics Innovation (ANDI), an organization that deploys a network-based
model for developing African health technologies, to identify concrete new
roles for north-south collaborations as part of these African health innovation
networks.17 This Article describes the role that such collaborations can play in
addressing gaps in capacity for management and transfer of technology and
knowledge from one stage of product development to another, thus supporting
commercialization strategies for locally developed health technologies. In
doing so, this Article helps to focus much needed attention on the importance
of local legal and business capacity building tailored specifically to the
commercialization of local health technologies as a critical part of a networkbased health innovation strategy.18

11

See, e.g., COUNCIL ON HEALTH RESEARCH FOR DEV. & NEW P’SHIP FOR AFR.’S DEV., supra note 2.
See Sustainable Development Goals, UNITED NATIONS DEV. PROGRAMME (2017), http://www.undp.
org/content/undp/en/home/sustainable-development-goals.html.
13
See AFRICAN UNION COMM’N, AGENDA 2063: THE AFRICA WE WANT (2015).
14
AFRICAN UNION COMM’N, SCIENCE, TECHNOLOGY AND INNOVATION STRATEGY FOR AFRICA 2024.
15
See generally BMC INT’L HEALTH AND HUM. RTS. SUPP. 2010 (series of twelve articles that discuss
African health innovation systems).
16
COUNCIL ON HEALTH RESEARCH FOR DEV. & NEW P’SHIP FOR AFR.’S DEV., supra note 2, at 66.
17
See AFRICAN NETWORK FOR DRUGS AND DIAGNOSTICS INNOVATION, FACILITATING HEALTH
INNOVATION IN AFRICA: STRATEGIC PLAN: 2016–2020 35 (2016).
18
See, e.g., Carlos M. Morel et al., Health Innovation Networks to Help Developing Countries Address
Neglected Diseases, 309 SCI. 401 (2005) (highlighting the growing ability of some developing countries to
undertake health innovations and the importance of innovation health networks as a mechanism for addressing
neglected diseases).
12
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Part I of this Article reviews the past performance of north-south
collaborations focused on diseases prevalent in Africa and identifies three key
limitations of traditional approaches to north-south collaborations. Part II
examines the shift in focus of development strategies toward regional capacity
building and networks and the corresponding changes in the collaboration
landscape. Part III uses past experience with collaboration efforts in African
biotechnology and ANDI’s current experiments, including a collaboration
between ANDI and Emory University, to generate guidelines for the design of
collaborations that focus on the support of regional innovation networks.
I.

NORTH-SOUTH COLLABORATIONS AS MECHANISMS TO ADDRESS
DISEASES PREVALENT IN AFRICA

North-south collaborations have long played a dominant role in global
health strategies intended to address particular diseases endemic in the south.19
Here “the south” refers to low- and middle-income (developing) countries and
“the north” to high-income (developed) countries as classified by the World
Bank.20 Africa, which is home to thirty-four of the world’s forty-eight least
developed economies as defined by the United Nations, has been the primary
focus of many such collaborations for decades.21 Until recently, these northsouth collaborations have been largely designed, financed, and controlled by
the northern partners with a concentration of R&D and decision making in the
north, a focus on disease rather than capacity to respond to disease, and a
reliance on public and philanthropic funds to finance the work.22
A. Traditional Models of North-South Collaboration
Traditional north-south collaborations to combat diseases prevalent in
Africa have generally taken one of the following forms: (1) nonprofit product
development partnerships (PDPs), (2) funding mechanisms to supply and
procure drugs and vaccines, (3) research institutes and platforms devoted to
research on neglected diseases, (4) pharmaceutical philanthropy, and (5)
19
See, e.g., Fred Binka, Editorial, North-South Research Collaborations: A Move Towards a True
Partnership, 10 TROPICAL MED. & INT’L HEALTH 207 (2005) (commenting on the evolving role of north-south
partnerships and the need to move away from historical models of scientific colonialism).
20
See World Bank Country and Lending Groups, WORLD BANK, https://datahelpdesk.worldbank.org/
knowledgebase/articles/906519-world-bank-country-and-lending-groups (last visited Nov. 15, 2017).
21
See About LCDs, UN OFF. OF THE HIGH REPRESENTATIVE FOR THE LEAST DEVELOPED COUNTRIES,
LANDLOCKED DEVELOPING COUNTRIES AND SMALL ISLAND DEVELOPING STATES, http://unohrlls.org/aboutldcs/ (last visited Jan. 20, 2018).
22
See, e.g., Binka, supra note 19; see also COUNCIL ON HEALTH RESEARCH FOR DEV. & NEW P’SHIP
FOR AFR.’S DEV., supra note 2, at 10–12, 16–17.
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overseas scientific training and technical assistance.23 Each of these categories
is described further below, and a summary of these models and their key
strengths and weaknesses is attached as the Appendix.
The first category, PDPs, has emerged as one of the most popular and
effective strategies for trying to bridge the gap between the growing scientific
and technological capabilities of mature economies and the needs of
developing economies.24 PDPs focus on the challenge of creating health
products and processes that meet the health needs of developing economies
where market incentives are lacking.25 They are typically nonprofit
organizations created as mechanisms for pooling funds from public and
philanthropic entities to support R&D in a particular disease or disease area.26
While each PDP has a slightly different structure, the majority of PDPs focus
on managing disease-specific projects rather than on conducting their own
R&D, forming partnerships with academic institutions and pharmaceutical
companies to implement their projects.27 Some of the most active and
successful PDPs in diseases endemic to African countries include the
Medicines for Malaria Venture (MMV), the Drugs for Neglected Diseases
Initiative (DNDi), the Global Alliance for TB Drug Development (TB
Alliance), the International AIDS Vaccine Initiative (IAVI), PATH, and the
Foundation for Innovative New Diagnostics (FIND).28 These PDPs, and others
like them, have successfully increased the amount of R&D in diagnostics and
drugs that target neglected diseases and have produced viable portfolios of
products in key disease areas.29
While the PDP model is one of the most successful approaches to date in
producing new medical therapies for neglected diseases, it has several

23
See, e.g., COUNCIL ON HEALTH RESEARCH FOR DEV. & NEW P’SHIP FOR AFR.’S DEV., supra note 2
(providing a detailed mapping of pharmaceutical innovation initiatives); see also Christina C. Melon et al.,
Correspondence, A Survey of South-North Health Biotech Collaborations, 27 NATURE BIOTECHNOLOGY 229
(2009); V. Muñoz et al., Can Medical Products Be Developed on a Non-Profit Basis? Exploring Product
Development Partnerships for Neglected Diseases, 42 SCI. & PUB. POL’Y 315, 324 (2015).
24
See, e.g., Joanna Chataway & James Smith, The International AIDS Vaccine Initiative (IAVI): Is It
Getting New Science and Technology to the World’s Neglected Majority?, 34 WORLD DEV. 16 (2006)
(examining the popularity of product based public-private partnerships and describing the characteristics of
one such partnership).
25
See id.
26
See, e.g., Claire Topal, An Interview with Rob Lin: The Value of Product Development Partnerships,
NAT’L BUREAU ASIAN RES. (Aug. 11, 2014), http://nbr.org/downloads/pdfs/cha/Lin_interview_081114.pdf.
27
See, e.g., id. (describing PDP structures).
28
See, e.g., Chataway & Smith, supra note 24, at 17; Muñoz et al., supra note 23, at 323 tbl.1, 330 n.6–
7 (providing a review of PDP models).
29
See, e.g., Muñoz et al., supra note 23, at 315–16.
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limitations that prevent it from being sufficient, on its own, to serve as a
comprehensive strategy for addressing neglected diseases. The PDP approach
is heavily reliant on public and philanthropic funding, which creates challenges
in achieving long-term financial sustainability of existing projects and limits
the number of new projects that can be undertaken. As a result of the nature
and limits of the funding, the range of diseases that receive the bulk of PDP
funds and effort is fairly narrow, with most of the funds going to research on
malaria, TB, and HIV/AIDS.30 While there are a number of early-stage
research projects underway in PDPs, the PDP model has had limited success in
implementing affordable innovation strategies and only a relatively modest
number of drugs and vaccines have reached the marketplace.31 Finally, this
model does little to build local and regional R&D capacity, focusing instead on
R&D efforts located largely in the north.32
The second category includes a range of alternative funding mechanisms to
support drug, vaccine, and diagnostics R&D, as well as the purchase of the
resulting health products.33 Some financial mechanisms provide support for
R&D, either in the form of grants, such as those provided by the Bill &
Melinda Gates Foundation, or prizes, such as the Global Grand Challenges
initiatives of the Bill & Melinda Gates Foundation and the United States
Agency for International Development (USAID).34 Other financial
mechanisms are used to finance purchases of health products.35 The four

30
See, e.g., Sarah E. Frew et al., A Business Plan to Help the ‘Global South’ in Its Fight Against
Neglected Diseases, 28 HEALTH AFF. 1760 (2009) (showing the important role of local private-sector
initiatives in addressing the local health problems in developing economies); NICK CHAPMAN ET AL., POLICY
CURES RESEARCH, G-FINDER, NEGLECTED DISEASE RESEARCH AND DEVELOPMENT: A PIVOTAL MOMENT
FOR GLOBAL HEALTH 76 (2016), (stating that 72% of total global investment in R&D for new products for
neglected disease went to HIV, malaria, and TB; 15% of the total came from private firms and the rest from
philanthropy and governments).
31
See, e.g., ELIZABETH PONDER & MELINDA MOREE, BIO VENTURES FOR GLOB. HEALTH, DEVELOPING
NEW DRUGS & VACCINES FOR NEGLECTED DISEASES OF THE POOR: THE PRODUCT DEVELOPER LANDSCAPE 16
(2012) (including detailed information on product pipelines).
32
See, e.g., Topal, supra note 26, (describing PDP structures). But see Binka, supra note 19, at 207;
Morel et al., supra note 18, at 402 (documenting examples of recent partnerships between PDPs and
companies in developing economies).
33
See, e.g., Frank Mueller-Langer, Neglected Infectious Diseases: Are Push and Pull Incentive
Mechanisms Suitable for Promoting Drug Development Research?, 8 HEALTH ECON., POL’Y & L. 185 (2013)
(examining and evaluating alternative push and pull strategies for encouraging investment in R&D for
neglected diseases).
34
See, e.g., id. at 188, 191; PAUL WILSON & AMRITA PALRIWALA, RESULTS FOR DEV. INST., PRIZES FOR
GLOBAL HEALTH TECHNOLOGIES 12 (2011); see also About Grand Challenges, GLOBAL GRAND CHALLENGES,
https://gcgh.grandchallenges.org/about (last visited Nov. 28, 2017).
35
See, e.g., Charlie Baran, Global Health Financing Mechanisms: Synergy, Duplication and
Distinction, GLOBAL FUND OBSERVER NEWSL. (Aidspan, Kenya, Afr.), Feb. 15, 2017, at 9, 9–11.

VERTINSKY GALLEYPROOFS2

2018]

3/30/2018 10:04 AM

HEALTH INNOVATION IN AFRICA

625

largest multilateral health financing mechanisms that account for the majority
of health product purchases are the Global Fund to Fight AIDS, Tuberculosis
and Malaria (Global Fund), the Global Alliance for Vaccines and
Immunization (Gavi), the World Bank’s Global Financing Facility in Support
of Every Woman Every Child (GFF), and Unitaid.36 These organizations have
developed a range of innovative financing mechanisms to support purchases of
essential medicines and vaccines, including, for example, the Advanced
Market Commitment, in which donors promise to purchase developing country
disease-focused drugs.37 These organizations have also developed a variety of
funding strategies, including transaction taxes such as airline ticket levies,
disease bonds, and public-private matching funds.38 While providing needed
resources and incentives for R&D, this approach is reliant on public and
philanthropic funds, research efforts take place primarily in the north, funds
support purchases of drugs and vaccines produced largely outside of Africa,
and the bulk of the funds target only a limited range of diseases.39 In addition,
evaluations of the major funds in particular have emphasized the need for
improved strategies for increasing the involvement of the private sector in
health financing.40
The third category includes research institutes and research platforms
focused on neglected diseases. Research institutes engage in early stage R&D
for neglected diseases, either as part of a university, a nonprofit, or a
pharmaceutical company. Examples include the Tres Cantos Open Lab
Foundation created by GlaxoSmithKline to support research on neglected
diseases,41 nonprofit institutes, such as the Infectious Disease Research
Institute (IDRI)42 (now perhaps better characterized as a PDP with its emphasis
on internal product development), and a large number of institutes and centers
within research universities. Research platforms can take the form of
collaborations designed to create mechanisms for sharing knowledge and
research for use in neglected diseases areas or mechanisms for collecting and
pooling research and coordinating research partnerships around a particular
36

See id.
See, e.g., Advanced Market Commitments (AMC), LENDING GROUP ON INNOVATIVE FINANCING FOR
DEV. (Feb. 27, 2009), http://www.leadinggroup.org/rubrique178.html.
38
See, e.g., DAMIEN PORCHER & DOMINIQUE KEROUEDAN, FRENCH MINISTRY OF FOREIGN & EUR.
AFF., HEALTH FINANCING: EVOLVING CONTEXT, EVOLVING METHODS 6–8 (2011).
39
See, e.g., id.
40
See, e.g., id. at 54–55 (evaluating performance of alternative financing mechanisms).
41
See, e.g., About the Open Lab, TRES CANTOS OPEN LAB FOUND., http://www.openlabfoundation.org/
about.html (last visited Jan. 20, 2018).
42
See, e.g., About, INFECTIOUS DISEASE RES. INST., http://www.idri.org/about/ (last visited Dec. 6,
2017).
37
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disease area.43 A good example of this platform strategy is WIPO Re:Search,
which provides a public research platform to support knowledge sharing in the
area of neglected tropical diseases.44 While this approach promotes knowledge
sharing and research capabilities, it again remains heavily reliant on public and
philanthropic funding, and most of the R&D activity continues to take place in
the north. In addition, the focus is largely if not exclusively on early-stage
research, while many of the challenges in addressing neglected disease occur at
the later stages of identifying promising potential products and moving them
through development and commercialization.
The fourth category is pharmaceutical philanthropy. This includes
philanthropic product donations from pharmaceutical companies, often
provided to non-governmental organizations for distribution.45 One of the
earliest and most successful drug donation programs was a program initiated
by Merck & Co., Inc. in 1987 for the donation of Mectizan, a human
formulation of the veterinarian drug ivermectin, to treat river blindness in SubSaharan Africa.46 Since then, a number of other pharmaceutical companies
have followed suit with their own drug donation programs.47 Pharmaceutical
philanthropy also takes the form of cash donations, technology transfers,
medical and technological expertise sharing, and internal research programs
focused on neglected diseases.48 While providing much needed resources and
expertise, pharmaceutical philanthropy is limited in magnitude and in scope. It
is subject to the discretion and interests of the pharmaceutical company donors
(as is all corporate philanthropy), targets a very limited range of diseases, and
does little to securely address long-term health needs.49
43
See, e.g., Strengthening Capacity, DRUGS FOR NEGLECTED DISEASE INITIATIVE, https://www.dndi.
org/strengthening-capacity/ (last visited Nov. 28, 2017) (describing DNDi’s role in setting up and supporting
regional disease-specific platforms and networks).
44
See WIPO RE:SEARCH, http://www.wipo.int/research/en/ (last visited Nov. 28, 2017) (“WIPO
Re:Search catalyzes the development of medical products for neglected tropical diseases, malaria, and
tuberculosis through innovative research partnerships and knowledge sharing.”).
45
See, e.g., Lisa Bero et al., To Give Is Better than to Receive: Compliance with WHO Guidelines for
Drug Donations During 2000–2008, 88 BULL. WORLD HEALTH ORG. 922, 922 (2010).
46
See, e.g., B. Colatrella, The Mectizan Donation Program: 20 Years of Successful Collaboration—A
Retrospective, 102 ANNALS TROPICAL MED. & PARASITOLOGY S7, S8 (2008); B. Thylefors et al., Operational
Lessons from 20 Years of the Mectizan Donation Program for the Control of Onchocerciasis, 13 TROPICAL
MED. & INT’L HEALTH 689, 689–90 (2008).
47
See, e.g., ACCESS TO MED. FOUND., ACCESS TO MEDICINE INDEX 2016 76–77 (2016).
48
See, e.g., John LaMattina, Even Pharma’s Good Deeds Are Criticized, FORBES (May 6, 2013, 8:40
AM), https://www.forbes.com/sites/johnlamattina/2013/05/06/even-pharmas-good-deeds-are-criticized (examining
some of the global health initiatives undertaken by pharmaceutical companies).
49
See, e.g., Cristina P. Pinheiro, Editorial, Drug Donations: What Lies Beneath, 86 BULL. WORLD
HEALTH ORG. 580 (2008) (describing problems that arise from lack of good procurement practices in drug
donation programs); Adam Robert Green, Drug Donations Are Great, but Should Big Pharma Be Setting the

VERTINSKY GALLEYPROOFS2

2018]

3/30/2018 10:04 AM

HEALTH INNOVATION IN AFRICA

627

The fifth category encompasses overseas technology transfer and training
programs.50 The technology and knowledge transfer model typically involves a
flow of educational programs, training, and technical assistance from the north
to the south. While some of these programs begin to address the deficit in legal
and business capacity, their primary focus seems to remain largely on
supporting education and institutional collaboration in the sciences. Most
programs have not been product-development focused and do not adequately
address the translation of technologies from lab to clinics to market.51 When
they are product focused, the programs tend to export models of drug
discovery and development that are better suited to well-developed markets
and typically lack mechanisms for long-term financing and sustainability.52
In summary, while making great strides in the study of neglected diseases,
these traditional collaboration models have not produced and sustained the
robust and comprehensive product development pipelines needed to respond
comprehensively and sustainably to the many Type II and Type III diseases
endemic to different regions within Africa.53 Although they vary in form, these
five approaches remain tied to a developed economy model of health product
discovery and development, relying primarily on public and philanthropic
funds, northern capacity for the development of new medical therapies, and
donor decision making about where to focus drug discovery and development
efforts.54 As a result, there has been a neglect of region-specific R&D needs
imposed by Africa’s growing chronic disease burden and emergent infections55
as well as a failure to adequately invest in the potential of local resources,
traditional knowledge, and local markets.56 These approaches have generally
Agenda?, GUARDIAN (Apr. 29, 2013, 7:01 AM), https://www.theguardian.com/world/2013/apr/29/drugcompany-donations-bigpharma (providing a critique of the reliance on drug donation programs as effective
response to neglected diseases).
50
See, e.g., Luis A. Salicrup, Opinion, NIH Forges R&D Partnerships in Developing Countries, 25
NATURE BIOTECHNOLOGY 976 (2007) (describing the role of United States National Institutes of Health Office
of Technology Transfer in north-south partnerships involving training in multidisciplinary skills needed in
technology transfer).
51
See Mary Moran, The Grand Convergence: Closing the Divide Between Public Health Funding and
Global Health Needs, PLOS BIOLOGY (Mar. 2, 2016), http://journals.plos.org/plosbiology/article/file?id=
10.1371/journal.pbio.1002363&type=printable.
52
See, e.g., Sara Al-Bader et al., Science-Based Health Innovation in Sub-Saharan Africa, in BMC
INT’L HEALTH AND HUM. RTS. SUPP., supra note 15, at S1.
53
See, e.g., Moran, supra note 51. For a definition of Type I, II and III diseases, see, for example, Mary
Moran, Debating the Scope of a Health Research and Development Convention, 91 BULL. WORLD HEALTH
ORG. 618 (2013).
54
See, e.g., Al-Bader et al., supra note 52.
55
See, e.g., Ama de-Graft Aikins et al., Commentary, Tackling Africa’s Chronic Disease Burden: From
the Local to the Global, GLOBALIZATION & HEALTH, Apr. 19, 2010, at 1.
56
See, e.g., Simiyu, supra note 3.
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not addressed the enabling elements of local product development, such as
management of intellectual property, licensing and technology transfer, market
analysis, business plan development, and business plan implementation. But
perhaps the most significant and pervasive limitation of these collaboration
models is the lack of mechanisms for ensuring financially sustainable
approaches to the development and commercialization of health products and
services targeted at meeting African health needs. 57
Even the most successful, product-focused collaborative efforts, such as
the PDPs described above, have struggled to attract the investment, business
and regulatory support, and human capital needed to move essential health
products like drugs and vaccines beyond early stages of R&D into the market.
Most of the funding for developing new treatments for neglected diseases
comes from foreign government and philanthropic sources.58 These funding
sources have been uncertain, limited in amount and duration, directed largely
to support research and early stage development rather than downstream
efforts at commercialization, and highly concentrated in three major disease
areas (HIV/AIDS, TB, and malaria).59 In addition, public and philanthropic
funding tends to be directed largely toward public and nonprofit institutions,
with only limited investment in the private for-profit sector.60 Private sector
funding, especially the sources of risk capital that support early stage ventures,
has been extremely limited or non-existent for technologies that target diseases

57
See, e.g., CHAPMAN, supra note 30, at 7 (stating that 40% of all neglected disease R&D funding goes
to organizations that rely on the U.S. government for more than 80% of their funding and that PDPs continue
to rely on the Bill & Melinda Gates Foundation, with nearly half of them receiving the majority of their
funding from the foundation); MARY MORAN ET AL., GEORGE INST. FOR INT’L HEALTH, G-FINDER,
NEGLECTED DISEASE RESEARCH & DEVELOPMENT: NEW TIMES, NEW TRENDS 7 (2009) (providing a survey of
global funding on neglected diseases and reporting that 87.6% of funding for R&D on neglected diseases came
from philanthropic and government sources).
58
See, e.g., CHAPMAN, supra note 30, at 5 (noting an overall decline in neglected disease funding
almost continuously since 2009 with 63% coming from the public sector, 21% from philanthropic funders, and
15% from industry—the highest industry funding share ever recorded by G-FINDER); MORAN ET AL., supra
note 57, at 54 fig.21 (showing a large increase in funding by philanthropic sources); see also David McCoy et
al., Global Health Funding: How Much, Where It Comes from and Where It Goes, 24 HEALTH POL’Y & PLAN.
407, 409–10 (2009).
59
See, e.g., WORLD HEALTH ORG., STATE OF HEALTH FINANCING IN THE AFRICAN REGION (2013); see
also, CHAPMAN, supra note 30, at 4 (noting that 71% of funds for neglected diseases go to HIV/AIDS, TB, and
malaria).
60
See, e.g., COMM’N ON THE PRIVATE SECTOR AND DEV., UNITED NATIONS DEV. PROGRAMME,
UNLEASHING ENTREPRENEURSHIP: MAKING BUSINESS WORK FOR THE POOR 35 (2004); Gulifeiya Abuduxike
& Syed Mohamed Aljunid, Development of Health Biotechnology in Developing Countries: Can PrivateSector Players Be the Prime Movers?, 30 BIOTECHNOLOGY ADVANCES 1589, 1590 (2012).
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that disproportionately affect the poor.61 As a result, the number of new drugs,
vaccines, and diagnostics and other medical devices developed specifically for
African markets has been small, and African biotechnology markets and the
institutional and regulatory systems to support them have remained
underdeveloped.62
B. Limitations of Traditional Collaboration Models as Mechanisms for
Capacity Building
Building on lessons learned from a review of traditional collaboration
models, a summary of which is included in the Appendix, and direct past
experience with north-south collaborations, this Article suggests that there are
three key, interconnected limitations of traditional north-south collaborations
as mechanisms for building African health innovation capacity. These
limitations, as further discussed below, are: (1) the neglect of local decision
making and capacity, (2) the failure to connect research efforts with
downstream processes for development and commercialization, and (3) the
absence of mechanisms to ensure long-term financial sustainability.63
1. Neglect of Local Decision Making and Capacity
The northern mode of biopharmaceutical discovery and development is
capital and technology intensive, highly regulated, and reliant on proprietary
intellectual property strategies and data protections. It is supported by welldeveloped capital markets and driven by market incentives. Underlying the
research, discovery, and commercialization process is a network of
relationships between stakeholders in the healthcare industry, including
scientists, government agencies, research universities and institutes,
pharmaceutical and biotechnology companies, medical device suppliers,
healthcare providers, investors, regulators, and patient groups. This network
61
See, e.g., Hassan Masum et al., Venture Funding for Science-Based African Health Innovation, in
BMC INT’L HEALTH AND HUM. RTS. SUPP., supra note 15, at S12 (discussing the “health innovation financing
gap in Africa” and limited venture capital investment in African life sciences opportunities, and noting lack of
infrastructure and experienced human resources as one of the barriers).
62
For a snapshot of current vaccines, drugs, and diagnostics for neglected diseases under development,
see Neglected Diseases: The Unrecognised Revolution in Global Health, POL’Y CURES RES.,
http://pipeline.policycuresresearch.org/ (last visited Nov. 28, 2017) (showing 485 products in the pipeline,
heavily concentrated in malaria, TB, and HIV/AIDS).
63
See, e.g., Laura Diaz Anadon et al., Making Technological Innovation Work for Sustainable
Development, 113 PROC. NAT’L ACAD. SCI. 9682, 9683 (2015) (providing insights into how to better harness
technological innovation for sustainable development: need to align current institutions, i.e. rules, norms, and
incentives, toward the goal of sustainable development, need for local decision making, and need to consider
all stages and scales of the innovation process).
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operates to move promising health technologies into the marketplace. As
described above, traditional collaboration models are largely designed around
this northern mode of health product innovation. Even when much of the R&D
work for neglected diseases takes place in the north, however, this approach
still works poorly as a means of satisfying the needs and constraints of markets
in developing economies.64 The products that result are often unaffordable and
not designed with local conditions in mind, and local development and
commercialization strategies flounder when components of the
commercialization network are either missing or inadequate to support
continued product development. This northern approach to pharmaceutical
innovation is likely to fail completely when the bulk of the research and
development work is shifted to developing economies, which face very
different regulatory frameworks, R&D infrastructure, and resource
constraints.65
The continued reliance on traditional northern health product discovery and
development approaches, despite their limitations in contexts of scarce
resources and neglected diseases, is not surprising given the concentration of
both funding and decision making in Western Europe and the United States
and the tendency to pursue innovation strategies and fund entities and diseases
that are familiar.66 While previous north-south collaborations to address
diseases endemic in Africa have varied in structure and goals over time, the
lack of control exerted by southern collaborators has remained largely
consistent, with only recent and gradual shifts toward a more balanced
partnership model and greater attention given to the divergent contexts of
innovation.67 The comparative lack of financial participation by African

64

See Al-Bader, supra note 52; Moran, supra note 51.
See, e.g., Clayton M. Christensen et al., Africa’s New Generation of Innovators: How Some
Enterpreneurs Have Succeeded in Creating New Markets Where Many Global Giants Have Failed, HARV.
BUS. REV., Jan.–Feb. 2017, at 128, 130–32 (describing the failure of large multinationals to exploit
opportunities in African markets and the benefits of a pull rather than a push approach to developing local
markets).
66
See, e.g., Linda Nordling, Africa Aims for Research Autonomy, 520 NATURE 142 (2015) (stating that
the majority of research done in Africa is still predominately financed and directed by global funders from
Western Europe and the United States).
67
See, e.g., Binka, supra note 19 (examining the shift of north-south collaborations toward partnership
models); see also Linda Nordling, Africa’s Fight for Equality, 521 NATURE 24, 25 (2015) (suggesting that
roots of unequal partnerships between north and south lie in how modern research in Africa began and
examining some recent measures to address inequality, such as the COHRED Fairness Index, which permits
institutions, funders, or other groups involved in research to receive certification if they engage in good
partnerships).
65
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governments and funders and the limits of existing African infrastructure and
pharmaceutical expertise have contributed to this partnership imbalance.68
Instead of seeking to transplant R&D strategies that have worked well in
developed markets for health technologies, north-south collaborations
supporting African capacity-building initiatives must find ways to optimize the
existing African infrastructure and work around—or address—its limitations.
The focus must be on medical therapies aimed at diseases endemic to African
countries, many of which are associated with large disease burdens but low
economic returns. The strategies must incorporate alternative innovation
models, including what have been called “frugal innovation”69 and “affordable
innovation” strategies,70 as well as efforts focused on adapting overseas
strategies and products to domestic market needs. The strategies must also be
designed with local institutional, legal, cultural, and political contexts and
relationships in mind. While recognizing the limitations, it is equally important
to harness the unique opportunities that the African continent offers, not just in
scientific capacity, but also through natural remedies, indigenous knowledge,
and biodiversity.71 Perhaps most importantly, the strategies must involve
decision making by African stakeholders, building on earlier “blueprint[s] on
how to foster collective self-reliance and sustainable development of the
continent”72 to further the African Union’s vision of “an Africa driven and
managed by its own citizens and representing a dynamic force in the
international arena.”73 While one of the key sticking points in expanding local
decision making continues to be the lack of investment in health innovation
capacity by the governments in many African countries, alternative funding
vehicles are being developed to support African-driven health innovation
strategies.74 In addition, models of balanced partnerships that emphasize the
decision-making roles of local partners are gaining traction.75
68

See, e.g., Nordling, supra note 67.
See, e.g., FRUGAL INNOVATION, http://frugalinnovationhub.com/en/ (last visited Nov. 28, 2017).
70
See, e.g., Frew et al., supra note 30, at 1766–67 (emphasizing the importance of affordable
innovation models built on local firm capabilities).
71
See, e.g., Solomon Nwaka, Harness Local Knowledge, 484 NATURE OUTLOOK S23 (2012) (noting
that “[a]bout 80% of the populations of Africa, Asia and Latin America meet their primary healthcare needs”
through reliance on local translational medicines and pointing out the need for coordinated mechanisms and
investment to support translation of local knowledge into products).
72
AFRICAN UNION COMM’N, supra note 14, at 12.
73
Id. at 11.
74
See, e.g., Nordling, supra note 66, at 142 (discussing the formation of the Alliance for Accelerating
Excellence in Science in Africa (AESA), a regional hub to award grants and develop African research
capacity).
75
See, e.g., Press Release, General Assembly, World Leaders Pledge to Reinvigorate ‘Global
Partnership of Equals’ to End Poverty, Hunger, Underdevelopment in Africa, U.N. Press Release GA/10748
69
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2. Failure to Conduct R&D Activities with a Product Focus in Mind
Many existing north-south initiatives have focused only on the training or
research aspects of health innovation.76 They have not adequately integrated
early-stage research efforts with downstream opportunities for product
development, nor have they addressed the lack of financial and institutional
support available to assist with moving early technologies into the
marketplace. Not surprisingly, therefore, researchers in many African research
institutions have not been encouraged to think entrepreneurially about how
products that could stem from their research efforts can support local health
needs. There is thus a need to complement upstream scientific training and
expertise with the more applied, product-focused skills, knowledge, and
incentives to pursue downstream development activities.77
Even where there is interest in moving promising discoveries into product
development, the long, risky, and expensive development and distribution
processes are fraught with challenges.78 Many African countries lack
established institutional, regulatory, and manufacturing capabilities to develop
and distribute health products and ensure they pass adequate quality and safety
standards. Intellectual property protection and data exclusivities, which play a
major role in the U.S. and European models of pharmaceutical innovation, are
less developed in many African countries.79 The lack of movement on national
biosafety frameworks for agricultural biotechnology provides a stark example
of the lag in governance capacity for biotechnology.80 Less than twenty of the
countries included in the African Union have established any laws, regulations,
guidelines or policies that relate to modern biotechnology.81 “The challenges
facing the continent on biotechnology and biosafety include lack of fund[s];
loss of trained technical expertise; slow development of the biotechnology
sector; inadequate Intellectual Property Rights infrastructure; government not
(Sept. 22, 2008). The Swiss Commission for Research Partnership with Developing Countries provides a set of
principles for north-south research partnerships that include shared decisions on objective, mutual trust,
sharing of information and responsibility, and a focus on local research capacity. See SWISS COMM’N FOR
RESEARCH P’SHIP WITH DEVELOPING COUNTRIES, A GUIDE FOR TRANSBOUNDARY RESEARCH PARTNERSHIPS:
11 PRINCIPLES (2d ed. 2014).
76
See, e.g., Salicrup, supra note 50.
77
See, e.g. Simiyu, supra note 3, at 1483 (summarizing findings from interviews with African
researchers about why African health technologies sometimes stagnate instead of reaching the market).
78
See, e.g., id.
79
See, e.g., Patrick Terroir, A New Look at Intellectual Property and Innovation in Africa, LES
NOUVELLES 178 (2016).
80
See, e.g., Diran Makinde et al., Status of Biotechnology in Africa: Challenges and Opportunities,
ASIAN BIOTECHNOLOGY & DEV. REV., July 2009, at 1, 7–8.
81
See, e.g., id. at 1 (discussing lag in the development of a governance capacity for biotechnology).
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taking a more active political role in promoting the technology and the issue of
public acceptance brought about by activism.”82 Financial markets are
similarly underdeveloped, with either limited or non-existent sources of risk
capital such as those provided by venture capitalists and angel investors.83
Thus, while there are promising discoveries coming out of African labs, these
discoveries too often remain undeveloped. Suitable intellectual property
management, licensing and technology transfer strategies that are based on the
realities and opportunities of local and regional markets, along with financing
strategies designed to support these efforts, should be an integral part of
innovation capacity building in Africa.84
3. Absence of Mechanisms to Ensure Long-Term Financial Sustainability
Finding sustainable, long-term funding remains one of the biggest
challenges in moving promising African health products through development
and into the marketplace.85 Financial support for many of the north-south
initiatives directed at neglected diseases are short-term in nature, often with
only a few years of guaranteed funding at a time. This limitation is the result of
heavy reliance on grant funding from public and philanthropic sources that are
limited in both amount and duration. The long time-horizons required to bring
a drug or even a medical device to the market do not fit well with the
budgeting and reporting needs of these public and philanthropic funders. There
is also a disconnect between the types of projects that public and philanthropic
funders typically support and the business needs of early stage companies
seeking to develop products. While government and philanthropic sources of
funding have helped to boost the pipeline for several neglected diseases, they
are often limited to research or seed funding for early stage ideas, with a dearth
of such funding for commercialization efforts.86
There are both formal and informal barriers that limit the use of public
funds to support the profit-making efforts of private companies, making it
difficult to fund the small- and medium-sized companies interested in taking
products to the market. In some of the developed economies, concerted efforts
have been made by government funders to adapt public funding programs to

82

Id.
See, e.g., Masum et al., supra note 61.
84
See, e.g., Frew et al., supra note 30, at 1770 (discussing the need for legal and business capacity
building, and suggesting the idea of a global health accelerator to provide intellectual property, business, and
financial support to grow local networks).
85
See, e.g., Masum et al., supra note 61.
86
See, e.g., Declan Butler, Neglected Disease Fund Touted, 465 NATURE 277 (2010).
83
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the needs of emerging businesses. The Small Business Innovation Research
(SBIR) and Small Business Technology Transfer (STTR) programs in the
United States87 and the Innovative Medicines Initiative in the European Union
have been designed with this goal in mind.88 Such efforts are largely absent in
developing economies, however.
Overall, public and philanthropic funding on their own—whether through
grants, tax credits, loans, and other push mechanisms, prizes and advance
purchase commitments, or even public programs to support the research and
development efforts of private companies—have not been adequate to support
and sustain health product development in African developing economies.
Moreover, the public and philanthropic funding come largely from foreign
countries, primarily countries in Western Europe and North America, with
very limited funding supplied by African governments. While there is great
variation in government spending across countries within Africa, the average
amount of national budgets devoted to health in 2013 was 9.8%, below the
15% target adopted by the African Union, and as low as 2% in some
countries.89 The African Union target of 1% of health expenditures directed to
research, adopted in 2006, has yet to be achieved by most of its members.90
Government investment in infrastructure, support for capacity building,
development of a cohesive policy framework, and strengthening of national
regulatory authorities are all required to encourage investment in local
pharmaceutical production.91
Private funding of African biotechnologies has also been woefully
inadequate in most African countries. The lack of significant domestic funding
of biopharmaceutical R&D and infrastructure by most African countries makes
87
The SBIR and STTR programs are U.S. federal government programs designed to support R&D
efforts of promising small businesses in the form of grant- or contract-based funding. See About SBIR, SBIR
STTR AM.’S SEED FUND, https://www.sbir.gov/about/about-sbir#sbir-program (last visited Nov. 28, 2017);
About STTR, SBIR STTR AM.’S SEED FUND, https://www.sbir.gov/about/about-sttr#sttr-program (last visited
Nov. 28, 2017).
88
The Innovative Medicines Initiative is Europe’s largest public-private initiative designed to
encourage the development of effective treatments for disease. See History—The IMI Story So Far,
INNOVATIVE MEDS. INITIATIVE, http://www.imi.europa.eu/about-imi/history-imi-story-so-far (last visited Nov.
28, 2017).
89
Laurent Musango et al., The State of Health Financing in the African Region, AFRICAN HEALTH
MONITOR, Mar. 2013, at 9, 12.
90
Ameenah Gurib-Fakim, African Governments Must Urgently Invest in Science and Research,
GUARDIAN (Sept. 30, 2015, 5:34 AM), https://www.theguardian.com/global-development-professionalsnetwork/2015/sep/30/african-governments-must-invest-in-science-and-research.
91
See, e.g., Jicui Dong & Zafar Mirza, Supporting the Production of Pharmaceuticals in Africa, 94
BULL. WORLD HEALTH ORG. 71 (2016) (describing the role of Ethiopia as a model country for local
investment in pharmaceuticals).
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attracting private-sector capital difficult.92 In many African countries, capital
markets are not mature, venture capital is largely absent, and limits in
purchasing power create risks that R&D costs may not be covered by returns
on investment.93 While in developed economies the private sector is the largest
biotechnology investor, in developing economies most of the investment in
health research is sponsored by the government or supported by philanthropic
organizations and is carried out in public and nonprofit institutions.94 Where
private-sector investors are present, they often concentrate their investments in
sectors where projects have shorter time horizons and are less risky and costly.
II. REGIONAL INNOVATION NETWORKS AS ALTERNATIVE PARADIGM
The Global Strategy encourages a departure from the traditional paradigm
of north-south collaboration discussed above, with its focus on donor-led R&D
initiatives to satisfy the needs of developing countries. It promotes greater
international engagement in the design of strategies for building R&D capacity
in developing countries in order to allow these countries to respond to their
own health needs. This Part examines the growing shift in focus of global
health development strategies toward regional capacity building and networks,
and explores corresponding changes in the collaboration landscape.
A. Shifting the Focus of Collaborations to African Health Capacity Building
While the challenges that many African countries face are daunting, its
young, growing population and uneven—but in some areas rapid—economic
growth, along with the wide and fast uptake of new technologies such as
mobile phone technologies, and an expanding middle class, are creating a new
view of Africa as a source of economic growth and opportunity.95 Change in
the collaboration landscape is occurring as international and domestic interest
in African biotechnology markets and business opportunities grow.96
The number of entrepreneurial biotechnology collaborations among firms
in developed economies and firms in some of the more advanced African
92
See, e.g., Katherine Bagley, Home-Base Biotech: African and International Efforts Are Boosting the
Continent’s Biotech Industry—For Now, SCIENTIST (Jan. 1, 2010), http://www.the-scientist.com/?articles.
view/articleNo/27903/title/Home-Base-Biotech/.
93
See, e.g., Masum et al., supra note 61.
94
See, e.g., Morel et al., supra note 18, at 401–02.
95
See WORLD HEALTH ORG. REG’L OFFICE FOR AFR., THE HEALTH OF THE PEOPLE: WHAT WORKS—
THE AFRICAN REGIONAL HEALTH REPORT 2014 xv (2014).
96
See, e.g., Melon et al., supra note 23, at 232; Halla Thorsteinsdóttir et al., Health Biotechnology
Innovation on a Global Stage, 9 NATURE REVS. MICROBIOLOGY 137, 138 (2011).
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markets has increased,97 as have south-south collaborations at both the firm
and government level.98 Many of the private-sector partnerships have emerged
as the result of entrepreneurial efforts by firms in more developed economies
in the south to find new business opportunities. Africa is now home to seven of
the ten fastest growing economies, a rapidly growing population, an expanding
middle class, and largely positive trends in private-sector growth.99 While
Africa’s pharmaceutical industry is one of the fastest growing, the industry
faces a shortage of specialists and a need for standardized regulation and
strengthened regulatory authorities.100 Further, most of the R&D and clinical
research continues to be performed by international companies, albeit
sometimes through local subsidiaries.101 Although north-south and south-south
collaborations among private-sector participants are growing, local
investments in infrastructure and human resources are needed to ensure that the
collaborative activities build local pharmaceutical capabilities.
At the state level, countries such as India and China have partnered with
the governments in some African countries to adopt frameworks for greater
regional cooperation that include investment in African science and technology
capacity. Recent examples include the China–Africa Science and Technology
Partnership Program (CASTEP) and the Africa–India Framework for
Cooperation.102 These government-led efforts focus primarily on either highlevel principles for cross-border cooperation or specific programs promoting
African research capacity and cross-border research collaborations. They
include few, if any, specific measures to build local African health-sector
development and commercialization capabilities.
The African Union has also engaged in a number of initiatives aimed at
strengthening regional health innovation capacity through collaborative efforts.
One such effort to build African regional science and technology capacity in
the biosciences is the establishment of Africa’s Science and Technology
Consolidated Plan of Action (CPA) in 2006 through the auspices of

97

See, e.g., Melon et al., supra note 23.
See, e.g., Thorsteinsdóttir, supra note 96, at 409.
99
Mohammed Dewji, Doing Business in Africa? Four Things You Should Know About, from One of the
Region’s Most Successful Entrepreneurs, WORLD ECON. F. (Jan. 13, 2017), https://www.weforum.org/agenda/
2017/01/four-trends-that-will-shape-the-african-business-landscape-in-2017/.
100
See, e.g., Bernd Rosenkranz, Africa’s Pharmaceutical Industry Boom Needs More Africans, QUARTZ
AFR. (Nov. 16, 2015), https://qz.com/550417/africans-need-to-make-their-mark-in-the-pharmaceuticalindustry-boom.
101
See, e.g., id.
102
See, e.g., Thorsteinsdóttir et al., supra note 96, at 139.
98
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NEPAD,103 an operational support arm of the African Union.104 The CPA
utilizes a regional network strategy for promoting research and development in
the biosciences.105 Other regional strategies focusing on the development and
support of African biopharmaceutical capacity include the Pharmaceutical
Manufacturing Plan for Africa, adopted by African Union member states; the
African Science, Technology and Innovation Policy Initiative, supported by the
United Nations Educational, Scientific and Cultural Organization (UNESCO)
along with African Union member states; the ResilientAfrica Network, funded
by USAID; and the Africa Technology Policy Studies Network, supported by
some of the African Union member states.106
As opportunities for collaboration increase in both public and private
sectors, and as regional innovation network strategies proliferate, it becomes
increasingly important to identify success factors for such strategies, where
success is defined in terms of the growth in local health innovation capacity.
This requires a more careful understanding of, and research into, what
innovation network strategies entail and how they can be used to support the
building of African health capacity.
B. The Emerging Strategy of Regional Health Innovation Networks
The theory of innovation networks has its foundations in social network
analysis, the study of how people, organizations, or other entities interact and
their relationships with each other.107 In this context, an African “health
innovation network” can be understood as a web of connections between and
among stakeholders with shared interests in the development of African
products and services to meet the health needs of African countries.108

103

See, e.g., Makinde et al., supra note 80, at 2.
See COUNCIL ON HEALTH RESEARCH FOR DEV. & NEW P’SHIP FOR AFR.’S DEV., supra note 2.
105
See CALESTOUS JUMA & ISMAIL SERAGELDIN, AFR. UNION & NEW P’SHIP FOR AFR.’S DEV., FREEDOM
TO INNOVATE: BIOTENCHNOLOGY IN AFRICA’S DEVELOPMENT app. c at 109 (2007); NEPAD and
Biotechnology, AFRICAN BIOSAFETY NETWORK OF EXPERTISE, http://nepad-abne.net/about-us/nepad-andbiotechnology (last visited Nov. 28, 2017).
106
See COUNCIL ON HEALTH RESEARCH FOR DEV. & NEW P’SHIP FOR AFR.’S DEV., supra note 2, at
annex 5 (providing a summary of major initiatives for strengthening pharmaceutical innovation in Africa). For
a discussion of the ResilientAfrica Network, see, for example, What is RAN?, RESILIENTAFRICA NETWORK,
http://www.ranlab.org/about-us/what-is-ran (last visited Jan. 20, 2018).
107
See, e.g., CHARLES KADUSHIN, UNDERSTANDING SOCIAL NETWORKS: THEORIES, CONCEPTS, AND
FINDINGS 26 (2012); see also Olav Sorenson, Innovation Policy in a Networked World 7 (Nat’l Bureau Econ.
Research Working Paper No. 23431, 2017).
108
See, e.g., Heidi Worley, The Emergence and Effectiveness of Global Health Networks, POPULATION
REFERENCE BUREAU (Dec. 2013), http://www.prb.org/Publications/Articles/2013/shiffman-global-healthnetworks.aspx.
104
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Networks create, support, and connect collaborations in a systematic way in
the pursuit of shared or complementary health innovation objectives. Strong
networks allow participants in the network to build social capital, where social
capital can be understood as “the sum of the actual and potential resources
embedded within, available through, and derived from the network of
relationships possessed by an individual or social unit. Social capital thus
comprises both the network and the assets that may be mobilized through that
network.”109 The hallmark of the innovation network approach is the centrality
of relationships and ties among stakeholders rather than the individual features
of the stakeholders themselves.
Innovation, the creation of new, technologically feasible,
commercially realizable products, processes and organizational
structures, emerges from the ongoing interaction processes of
innovative organizations such as universities, research institutes,
firms . . . government agencies, venture capitalists and others.
These organizations generate and exchange knowledge, financial
capital, and other resources in networks of relationships that are
embedded in institutional frameworks on the local, regional,
national and international level.110
The emphasis in network-based innovation strategies is placed on mapping
existing local capacities and fostering relationships to connect these areas of
local capacity in ways that support discovery, development, and
commercialization of new technologies and products. Where capacities are
understood in terms of the ability to make and distribute useful health products,
the study naturally encompasses all of the relationships needed to move a
product through the development process and into distribution. This includes
not only science and technology, but also the financial, business, legal, and
regulatory aspects of the process, as well as some understanding of the
competitive landscape and potential consumer base. It encompasses very
different types of stakeholders, including universities, scientists, entrepreneurs,
state and local regulators, public and philanthropic funders, private sector
funding sources, healthcare providers, healthcare insurers, and consumers.
Legal professionals must also be included, since scientists, entrepreneurs,
investors, and end-users must be able to rely upon harmonized regulatory
schemes and reliable enforcement of contracts, along with business
professionals skilled in product development and market analysis. Of
109
Janine Nahapiet & Sumantra Ghoshal, Social Capital, Intellectual Capital, and the Organizational
Advantage, 23 ACAD. MGMT. REV. 242, 243 (1998) (citation omitted).
110
Petra Ahrweiler & Mark T. Keane, Innovation Networks, 12 MIND & SOC’Y 73, 76 (2013) (citations
omitted).
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necessity, networks also encompass and respond to the specific cultural,
political, and economic contexts within which these stakeholders operate.
III. BUILDING AND SUPPORTING HEALTH INNOVATION NETWORKS THROUGH
COLLABORATION: AN EXAMPLE
While a growing number of global health policymakers have
acknowledged the importance of regional health capacity building and
recognized the role of regional networks as strategies for capacity building,
designing initiatives that are effective in building sustainable health innovation
capacity has proven to be challenging. North-south collaborations can play a
critical role in these efforts, but only if they are designed with local needs,
opportunities, and constraints in mind. This Part draws from past experiences
with collaboration efforts in African biotechnology, along with current
collaboration strategies employed by ANDI, to generate guidelines for the
design of collaborations that support regional innovation networks as a
capacity building strategy.
A. ANDI: An Example in the Construction of Health Innovation Networks
It is the challenge of integrating early-stage opportunities into a robust and
financially viable product development and commercialization process that
continues to be the weak link in many of the most recent regional innovation
strategies. ANDI was established in 2008 with the goal of responding to this
challenge by developing an African regional innovation network focused
specifically on the development and commercialization of African
technologies. ANDI is an African led and owned organization formed with the
goal of creating a sustainable, organized network for African health innovation
by “linking expertise and capacities from across the continent to costeffectively build common technology platforms and manage pharmaceutical
projects.”111 ANDI seeks, through partnerships with other African initiatives
and collaborators from the north and the south, to develop sustainable, panAfrican innovation networks that move from early-stage research to product
development and manufacture of health technologies—including diagnostics,
drugs, vaccines, and medical devices—in disease areas that disproportionately
impact African countries.112 It employs an innovation-network approach to
capacity building that concentrates on identifying, building, and strengthening
111
Regional Network for Drugs and Diagnostics Innovation Exemplified by ANDI: Background Paper
for Executive Board, supra note 4, at fig.1.
112
See AFRICAN NETWORK FOR DRUGS AND DIAGNOSTICS INNOVATION, supra note 17, at 14–16.
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relationships between different participants that can contribute to product
development processes.113
ANDI’s divergence from traditional approaches to addressing neglected
diseases results from the very different orientation of innovation network
strategies and the anchoring of such strategies inside the African continent. In
line with the innovation-network approach, ANDI’s early efforts involved
mapping available African resources to develop health technologies and
identifying gaps where additional resources are needed.114 ANDI has since
moved into the design and support of networks that bring together those
technologies and actors that are needed to create and implement sustainable
business plans and to successfully commercialize health products within
African markets. ANDI hopes to use some pilot examples of technologies
moving through the network to demonstrate that African markets are ripe for
health product innovation even with little financial support from African
governments.
Reflecting the central role of relationships among people, organizations,
and institutions in network theories of innovation, ANDI’s current strategic
plan focuses specifically “on the brokerage of partnerships and fostering of
collaborations” to build health-product focused networks.115 A key part of
ANDI’s strategy rests on its ability to identify, select, and broker the kinds of
south-south and north-south collaborations needed to facilitate the validation,
scale-up, registration, and marketing of promising African health technologies.
Partners must be chosen with care since the value of the network lies, in part,
in the value of the relationships that are created among network participants—
which can be understood as the social capital of the network.116 North-south
collaborations will be most valuable as part of a network strategy if they can
increase the social capital of the network, either by filling a gap in the network
or by providing tools and resources to support necessary connections among
existing participants in the network. Legal and business professionals will play
a critical role in filling these gaps. Scientists, entrepreneurs, investors, and endusers must be able to rely on harmonized regulatory schemes and reliable
enforcement of contracts, and product development must be informed by a
knowledge of market opportunities and constraints and an ability to evaluate
and implement successful business plans. ANDI’s strategy includes the design

113
114
115
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See id.
See id.
Id. at 11.
See Nahapiet & Ghoshal, supra note 109, at 243.
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of regional platforms that can provide affordable professional services as the
local professional workforce develops.117
B. Three Guidelines for North-South Collaborations in Innovation Networks
The three limitations of traditional north-south collaborations discussed
above become even more important in this kind of regional network-based
strategy. Neglect of local capacity and decision making will not lead to
effective capacity building, a failure to connect research with development and
commercialization runs contrary to the idea of building an innovation network,
and financial sustainability will be essential for the network to flourish and
attract new participants.118 ANDI employs three guidelines in its design of
collaborations to address these limitations and respond to the needs of an
innovation network strategy: (1) focus on locally driven product development
processes, (2) employ a product-focused approach to health innovation that
connects research with development and commercialization, and (3) build
strategies for financial sustainability into the design of both the collaboration
and the network.119 These three guidelines are interconnected, and a successful
program design needs to reflect and plan for all three.
1. Focus on Locally Driven and Designed Capacity Building to Advance
Local Technologies
The starting point for an ANDI collaboration is a local need or opportunity
that an African entity or individual can pursue primarily within an African
market. In some cases, this will be a new or underdeveloped market, and the
participants in the collaboration will be navigating its development. ANDI has
selected over forty public and private institutions from across the African
continent with expertise and capacity in a variety of different health R&D
areas to function as Centers of Excellence, providing focal points where
promising new technologies are likely to emerge, with the expectation of
growing this number over time.120 These Centers of Excellence serve as
sources of promising new African technologies.
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See AFRICAN NETWORK FOR DRUGS AND DIAGNOSTICS INNOVATION, supra note 17, at 20.
See, e.g., Kevin Marsh, How Africa Can Close Its Continent-Wide Science Funding Gap,
CONVERSATION (Apr. 12, 2016, 10:03 AM), http://theconversation.com/how-africa-can-close-its-continentwide-science-funding-gap-55957.
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See, e.g., id.
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See, e.g., AFRICAN NETWORK FOR DRUGS AND DIAGNOSTICS INNOVATION, supra note 17, at 15.
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ANDI begins with a rigorous process for selecting those technologies
likely to succeed as products and then tackles the problem of building
pathways to move these technologies through the long, risky, and expensive
development, commercialization, and distribution processes. ANDI’s focus is
on building the networks that will encompass and connect the various
participants needed to move health technologies through all the stages of
product development and commercialization.121 ANDI’s collaborations are
designed to be opportunistic, supporting promising technologies as they
emerge from the Centers of Excellence and seeking to train the local
innovators in the areas that they need to progress their technologies down a
product development and commercialization pathway. As these projects
advance, participants in the process form relationships with each other and
gain an understanding of the process and their role in that process,
strengthening the network. Since the institutional and technological contexts
may shift over time or across regions, and the relationships between
participants and organizations have value as part of the network, collaborations
that continue over time with the ability to review and learn from past
performance and adapt to new circumstances will be most effective,
reinforcing the need to invest in social capital.
2. Employ a Product-Focused Approach to Health Innovations
ANDI takes an intentional approach to the design of the network that is
based on existing resources and product development goals. The network must
be capable of moving promising health technologies through
commercialization and into the marketplace at prices and in forms that will
meet local health needs. A product’s successful move from lab to market
requires careful selection of early-stage technologies focusing not just on
scientific merit, but also on the requirements of these technologies at later
stages of development and the likelihood of finding resources for their further
development. Moving technologies beyond the early stages of development
requires a viable business plan, attention to the intellectual property and
regulatory strategies needed to turn the technology into a financially
sustainable product, and financial and business strategies for getting products
to market.122 In nascent domestic markets these strategies will often serve as
prototypes for future product development efforts, evolving over time as local
market conditions change.
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See, e.g., id.
See, e.g., id. at 28–31.
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ANDI’s network-based approach includes the development of regional
platforms to support local health technologies at critical junctures in the
product development process. These regional platforms will provide African
scientists with the tools and knowledge they need to move promising
technologies into the product development process. They will provide African
entrepreneurs with the skills and support needed to develop and implement
business plans. This platform-based approach provides a way of economizing
on the legal and business expertise required to support product development
while domestic capacity grows, as well as a training ground for new legal and
business professionals.123 North-south collaborations such as the partnership
between ANDI and Emory University, described below, are being used to help
in the design and implementation of these platforms.
3. Incorporate New Financial Mechanisms for Long-Run Sustainability
ANDI is currently exploring ways of combining public, philanthropic, and
private funds to support a portfolio of health projects with mechanisms for
providing reasonable returns to stakeholders or investors, while at the same
time protecting the public interest in ensuring accessible and affordable health
products.124 While there are significant differences in the financial markets
facing African product developers, organizational experiments with alternative
funding models for the “valley of death” confronting many new
biotechnologies being developed in the United States can nonetheless usefully
inform African experiments with alternative funding models.125 One such
organizational innovation in funding models for neglected diseases is
underway at Emory. Emory has formed a special drug-development vehicle
designed to confront the challenges of financing drugs that may not be
associated with large economic markets through a product portfolio and hybrid
financing strategy. This model is called the Drug Innovation Ventures at
Emory, LLC (DRIVE).126
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See, e.g., id. at 16.
See AFRICAN NETWORK FOR DRUGS AND DIAGNOSTICS INNOVATION, supra note 17, at 49, 50 tbl.IV.
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The term “valley of death” in pharmaceutical R&D refers to the gap between academic-based
pharmaceutical discoveries and their commercial development, a gap that is full of risk and expense, and
difficult to finance. See, e.g., Liza Vertinsky, Making Knowledge and Making Drugs? Experimenting with
University Innovation Capacity, 62 EMORY L.J. 741, 243 n.10 (2013).
126
See, e.g., DRIVE, http://driveinnovations.org/ (last visited Nov. 29, 2017); see also Vertinsky, supra
note 125, at 790–808 (discussing the case study of DRIVE).
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C. The ANDI–Emory Collaboration
ANDI’s collaboration with Emory provides an example of a program
design that reflects all three guidelines. ANDI collaborated with Emory in
2015 with two main goals.127 The first goal is to equip African scientists and
entrepreneurs with the multidisciplinary skill set needed to move African
health technologies from early-stage ideas to product commercialization. The
second goal is to design new strategies to support selected technologies
through the valley of death—the costly and risky phases of later-stage product
development—in African markets.
The collaboration has developed a two-phase program (the “Program”) to
support these goals.128 Phase I currently (1) identifies talented African
scientists with technological innovations; (2) provides the scientists with a
focused, experiential learning curriculum in the legal, business, technical, and
translational skills and knowledge needed to advance local health technologies
through product development; and (3) for selected technologies, provides
assistance in developing the business case for further investment and support.
The Program is designed to be opportunistic. It responds to local promising
technologies and seeks to train the local innovators in what they need to know
to move their technologies down a product-development and
commercialization path. The Program is also adaptive, absorbing lessons
learned from each year to alter program design for the following year. Repeat
relationships between the north and south partners are a critical part of this
adaptive process.
Phase II of the Program will focus on the design of regional innovation
platforms to provide the financial, legal, and entrepreneurial support and
services needed to translate early-stage technologies into products. Finding
ways of achieving financial sustainability both for technologies and for the
regional networks is a critical part of Phase II. As the networks mature, they
will hopefully provide product-development support not only to health
technologies coming out of ANDI’s Centers of Excellence, but also to
technologies from other interested African institutions. Mature innovation
platforms will be equipped to provide advice and support on business and legal
127
See Outreach, LIOTTA RES. GROUP, https://scholarblogs.emory.edu/liotta/outreach/ (last visited Nov.
29, 2017).
128
See, e.g., ANDI-EMORY Partnership in Action: Initiative Aims to Fill a Glaring Gap in Advancing
Health Technologies from Lab to Market in Africa, ANDI NEWSL. (African Network for Drugs & Diagnostics
Innovation, Eth., Afr.) Aug. 9, 2016; see also Claire Cooper, Health Technology Innovation in Africa:
Goizueta’s Core Values at Work, GOIZUETA STUDENT BLOG (Oct. 31, 2016), https://www.voiceofgoizueta.
com/health-technology-innovation-in-africa-goizuetas-core-values-at-work/.
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aspects of technology progressions, including, but not limited to, the
management of intellectual property, technology transfer, licensing, feasibility
and market analysis, business plan development, and marketing. Separate
hybrid public-private funding mechanisms will be used to support the
development of the technologies, as further discussed below.
The Program adheres to the three guidelines discussed in this Article. First,
the selection of technologies and scientific collaborators is done locally,
coordinated by ANDI. Second, all activities are product focused, with an
emphasis on building and supporting product-development pipelines. Third,
the scientists of selected technologies work with advisors to develop a
sustainable financial model.
In working on innovative financial models, ANDI and Emory are exploring
ways of adapting a unique approach to the financing of R&D for neglected
diseases developed at Emory to support African R&D projects. Using proceeds
from a royalty monetization of Emtriva, a leading HIV therapy,129 Emory has
been experimenting with ways of overcoming what is often referred to in the
biopharmaceutical industry as the valley of death. It has developed a model
designed to address two key challenges in the translation of promising drug
candidates into products: (1) coordinating upstream discovery activities with
downstream development and commercialization; and (2) finding sustainable
funding for the drug development process, particularly for drugs that treat
neglected diseases.
The model involves creating platforms of expertise at particular levels of
the drug discovery and development process that can support a portfolio of
drug candidates as they move through lead optimization and pre-clinical
testing and into proof of concept clinical trials.130 This platform approach
allows for cost and risk sharing both in the drug-development process and for
the funders of this process. The first part of the model was implemented in
2008, when Emory established the Emory Institute for Drug Development
(EIDD), an institute that has an applied drug development agenda and drug
development capabilities. EIDD has equipment and laboratory facilities
necessary to transition drug-discovery efforts into early drug development
projects. The second part of the model was implemented in 2012, when Emory
129

See, e.g., Michael Terrazas, Drug Royalty Sale Fuels Emory Research, EMORY REP., Aug. 1, 2005, at

1, 1.
130
For a basic overview of the U.S. drug discovery and development process, see, for example, The
Drug Development Process, U.S. FOOD & DRUG ADMIN. (June 24, 2015), https://www.fda.gov/ForPatients/
Approvals/Drugs/default.htm.
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created a new kind of drug-development company, a not-for-profit company
wholly owned by Emory called DRIVE. DRIVE is EIDD’s industrial partner,
providing the financial, business, project management, and regulatory expertise
to move drug candidates through lead optimization and pre-clinical testing into
proof of concept clinical trials. Successful drug candidates are out-licensed to
pharmaceutical companies, spun out into venture-backed companies, or
partnered with philanthropic or government initiatives. DRIVE focuses on an
area of expertise rather than a specific drug, seeking to exploit Emory’s human
capital and research capabilities in the area of infectious diseases to identify,
develop, and commercialize drugs. It focuses on the development of smallmolecule drugs that address viruses that have significant global health impact,
including RSV (respiratory syncytial virus), HCV (the hepatitis C virus),
influenza viruses, Zika, and dengue fever virus. DRIVE provides a platform
that offers drug development and business expertise and sustainable financing
to support the translation of promising discoveries into drugs that will treat
viral diseases of global importance.
The basic idea behind this approach is to create an organizational structure
that can combine both public and private financing to support a portfolio of
drug-development projects that include both commercially viable drugs and
drugs for neglected diseases endemic in financially constrained economies. It
takes a portfolio approach to drug development in which both costs and
revenues are pooled across alternative drug projects. This approach
economizes on costs by sharing facilities and pooling resources. It also
provides a way of attracting financing by allowing for a mix of public and
private investments in a portfolio of drug projects, some of which may
generate substantial licensing revenues and some of which may need financial
support. DRIVE seeks to attract and combine a mix of funding, including
donor, government, venture, and industry funding to address unmet needs for
treatments for viral diseases. A key aspect of this organizational structure is the
modularity of the research, early-stage development, and later-stage financing
and project management functions within a single not-for-profit university
system. Different incentive structures are used within each entity or unit, but
they all share a common organizational home and not-for-profit status. This
preserves room for the public-interest aspects of project choice and broadens
the types of funders that may be interested in supporting drug-development
processes.
Innovative financing approaches such as this offer ideas for structuring
public and private sector participation in supporting promising technologies as
they emerge from ANDI’s Centers of Excellence. The idea of using platform

VERTINSKY GALLEYPROOFS2

2018]

3/30/2018 10:04 AM

HEALTH INNOVATION IN AFRICA

647

approaches to allow diversification of risk and to support combinations of
public and private support may provide a way of securing the financial support
needed to reach financial self-sustainability.
CONCLUSION
While promising technologies designed to meet local and regional health
needs are emerging in increasing numbers from public and private research
labs and workshops in many African economies, these technologies are
unlikely to progress without the type of integrated capacity-building work that
is explored in this Article. The health-innovation network approach that we
have described provides a concrete strategy for implementing the regional
innovation networks that are at the heart of Agenda 2030 for Sustainable
Development, the Global Strategy and Plan of Action on Public Health,
Innovation and Intellectual Property, as well as the African Union’s Agenda
2063. While north-south collaborations form an important part of this network
strategy, they must be responsive to the unique needs and opportunities of an
African regional innovation network. Drawing from ANDI’s experience in
designing an African health innovation network, as well as lessons learned
from past and current collaboration efforts, we have provided three guidelines
for the design of effective north-south collaborations to support African health
innovation networks. Network strategies rely on scale and, if successful, this
collaboration model can be adopted by other partners seeking to work together
to build African health innovation capacity.
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APPENDIX
Table: Categorizing Traditional North-South Collaboration Strategies
Type of
Collaboration
Product
Development
Partnerships

131

Examples
MMV, DNDi, TB
Alliance,
International AIDS
Vaccine Initiative,
Global Antibiotic
Research and
Development
(GARD), PATH,
FIND.131

Description
PDPs are typically
nonprofit
organizations that
use funds from
public and
philanthropic
entities and form
partnerships with
public and private
institutions to
implement
projects. They
focus on one or a
specified group of
diseases, with
R&D based
primarily in the
North. MMV and
DNDi focus on
drugs for malaria
and neglected
diseases
respectively, FIND
focuses on
diagnostic tests for
neglected diseases,
and PATH spans
work on vaccines,
drugs, diagnostics,
devices, and
system and service
innovations.

For a review of PDPs see, for example, Muñoz et al., supra note 23, at 324.

Key
Strengths and
Limitations
Strengths: (1)
Increases
R&D of
diagnostics
and drugs that
target
neglected
diseases; (2)
has resulted
in a viable
portfolio of
products; and
(3) has helped
to develop
and put a
number of
products
(largely based
on
reformulation
of existing
products) on
the market.
Limitations:
(1) Heavy
reliance on
public
funding and
philanthropy;
(2) limited
mechanisms
for achieving
long term
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financial
sustainability;
(3) focuses
primarily on a
small number
of diseases;
(4) limited
success in
transitioning
early stage
technologies
through to
commercial
products; (5)
does little to
address
capacity
building
(although
DNDi tries
to); and (6)
largely
located
outside of
Africa and
reliant on
traditional
R&D
strategies.132
Pharmaceutical
Philanthropy/
Drug Donation
Programs

Drug Donation
Programs e.g.,
Merck Mectizan
Drug Donation
Program, Pfizer’s
Diflucan Partnership
Program, Novartis
distribution of
Imatinib to eighty-

Philanthropic
product donations
from
pharmaceutical
companies, often
provided to nongovernmental
organizations for
distribution.

Strengths: (1)
Provides lifesaving
treatments;
and (2)
bridges
immediate
needs until
other options

132
See, e.g., CHERI GRACE, HUMAN DEV. RES. CTR., PRODUCT DEVELOPMENT PARTNERSHIPS (PDPS):
LESSONS FROM PDPS ESTABLISHED TO DEVELOP NEW HEALTH TECHNOLOGIES FOR NEGLECTED DISEASES 6–7
(2010); James Smith, Context-Bound Knowledge Production, Capacity Building and New Product Networks,
17 J. INT’L DEV., 647, 650–54 (2005).
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Mechanisms:
(a) Purchasing
Drugs and
Vaccines
(b) Grants and
Prizes

133
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one
countries, Merck

can be
developed.

(Germany)
Praziquantel
donation program,
etc.

Limitations:
(1) Depends
on
availability of
approved
treatment; (2)
does not
always reflect
domestic
health
priorities and
needs; (3)
lacks
mechanisms
to ensure
sustainability;
(4) lack of
sustained
quality
control
systems in
Africa; and
(5) may
negatively
impact local
production.133
Strengths: (1)
Provides
funds for life
saving
treatments;
(2) bridges
immediate
needs until
other options
can be found;
and (3)
catalyzes

Global Fund, GAVI,
UNITAID.
Grants and Prizes:
Bill & Melinda
Gates Foundation
(BMGAF), Global
Grand Challenges
initiatives of BMGF,
USAID, DFID,
Canada.

See, e.g., Bero et al., supra note 45.

(a) Financial
mechanisms to
procure and supply
needed drugs for
developing
economies.
(b) Financial
mechanisms to
support product
R&D and/or
technology
development.
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product
R&D.

Research
Institutes,
Research
Platforms, and
Programs for
Research
Coordination

Research Institutes:
Pharmaceutical:
Novartis Institute
for Neglected
Disease,
GlaxoSmithKline
Tres Cantos
Research Institute.
R&D initiatives
within universities
and national R&D
centers.

Research Institutes:
R&D institutes
focused on early
stage product
discovery for
neglected diseases,
either as part of a
university, a
nonprofit, or as
part of a
pharmaceutical
company.

Limitations:
(1) Limited
number of
diseases as
targets; (2)
does not
address local
innovation
capacity; (3)
does not
address
sustainable
supply chain
issues in
developing
countries; (4)
limited
financial
capacity; and
(5)
sustainable
financing for
the critical
next steps of
going to
market with
products or
access not
addressed.
Strengths: (1)
Helping to
generate a
critical mass
of new
product leads;
(2) promoting
knowledge
sharing,
including
pooling
patents; and
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Research Platforms:
WIPO RE:Search,
Medicines Patent
Pool.
Research
Coordination:
UNICEF / UNDP /
World Bank/ WHO
Special Program for
Research and
Training in Tropical
Diseases (TDR), the
International
Agency for
Research on Cancer
(IARC).

Technology
transfer and
training
programs

USAID HESN
initiatives,
Wellcome Trust
H3Africa initiative
focusing on
genomics, DELTAS
program now run
through African
Academy of
Sciences.

Research
platforms:
Collaborations
designed to create
mechanisms for
sharing knowledge
and research for
use in neglected
diseases areas.
Research
coordination:
Mechanisms for
collecting and
pooling research
and researchers
around particular
disease area.

Technology and
knowledge transfer
model involving
educational
programs and
technical assistance
flowing from north
to south. Includes a
number of basic
research, education
and institutional
capacity-building
initiatives.

[Vol. 67:619

(3) providing
education and
capacity
building
through
university
education or
targeted
capacity
building.
Limitation:
(1) Largely
located
outside of
Africa with
limited
impact on
local capacity
building; and
(2) focus on
early stage
research and
discovery
with no
product
development.
Strengths: (1)
Supporting
education and
institutional
collaboration;
and (2)
supporting
basic research
and
knowledge
generation.
Limitations:
(1) No
product
focused
initiatives and
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do not
address
translation of
technologies
from lab to
clinics to
market; (2)
export of
northern
models and
questions to
the south; and
(3) lack of
mechanisms
for long term
financing and
sustainability.

